Taeang Arai
Overview
Explore the profile of Taeang Arai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
1128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morita T, Ichiyama S, Ito M, Ozaki S, Arai T, Atsukawa M, et al.
J Nippon Med Sch
. 2025 Mar;
92(1):88-96.
PMID: 40058840
Background: Psoriasis is accompanied by systemic inflammation that includes the liver. The fibrosis-4 (FIB-4) index was developed to predict significant liver fibrosis. The present study evaluated the effects of biologics,...
2.
Miwa T, Tsuruoka M, Ueda H, Abe T, Inada H, Yukawa-Muto Y, et al.
J Gastroenterol
. 2025 Mar;
PMID: 40053108
Background: Covert hepatic encephalopathy (CHE) leads to devastating outcomes in patients with cirrhosis. This study aims to elucidate the current management and future perspectives of CHE in Japan. Methods: A...
3.
Hiraoka A, Kudo M, Tada T, Hatanaka T, Kakizaki S, Kariyama K, et al.
Oncology
. 2025 Feb;
:1-23.
PMID: 39900019
Background/aim: Rapid development of systemic treatments has resulted in improved prognosis for unresectable hepatocellular carcinoma (uHCC) patients. Since immune therapy shows a favorable therapeutic efficacy, use of tumor markers as...
4.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39844393
Background And Aim: To assess the relationship between survival outcomes and subtypes of radiological progressive disease (PD) in patients with hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atezo/Bev). Methods:...
5.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, et al.
Cancer Med
. 2025 Jan;
14(2):e70618.
PMID: 39840727
Aim: This study aims to investigate the clinical utility of the derived neutrophil-to-lymphocyte ratio (dNLR) and the Geriatric Nutritional Risk Index (GNRI) in predicting treatment outcomes for patients with unresectable...
6.
Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, et al.
J Gastroenterol Hepatol
. 2025 Jan;
PMID: 39762722
Aim: This study aimed to compare the prognostic performance of the risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment. Methods: Among 449...
7.
Ichiyama S, Ito M, Ozaki S, Arai T, Atsukawa M, Iwakiri K, et al.
J Nippon Med Sch
. 2025 Jan;
91(6):534-540.
PMID: 39756942
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is positively associated with the prevalence and severity of psoriasis. The fibrosis-4 (FIB-4) index was developed to predict significant liver fibrosis. Using the...
8.
Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, et al.
Sci Rep
. 2025 Jan;
15(1):72.
PMID: 39747852
In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the...
9.
Ishiba H, Fujii H, Kamada Y, Sumida Y, Takahashi H, Seko Y, et al.
Hepatol Commun
. 2024 Dec;
9(1).
PMID: 39670882
Background: Various noninvasive tests can be used to identify high-risk groups of patients with metabolic dysfunction-associated steatotic liver disease/steatohepatitis (MASLD). In this study, we compared the diagnostic performance of serum...
10.
Kim J, Ito T, Arai T, Atsukawa M, Kawanaka M, Toyoda H, et al.
Diagnostics (Basel)
. 2024 Nov;
14(22).
PMID: 39594165
The Fibrosis-4 (FIB-4) index is widely recommended as a first-tier method for screening advanced hepatic fibrosis; however, its diagnostic performance is known to be suboptimal in patients with Type 2...